단일클론항체 치료 시장 분석 및 예측 : 유형별, 제품 유형별, 기술별, 용도별, 최종 사용자별, 기능별, 프로세스별, 도입 형태별, 개발 단계별(-2035년)

Monoclonal Antibody Therapy Market is anticipated to expand from $186.5 billion in 2024 to $497.5 billion by 2034, growing at a CAGR of approximately 12.4%. The Monoclonal Antibody Therapy Market encompasses the development and distribution of lab-engineered molecules designed to serve as substitute antibodies, restoring or enhancing immune system function. These therapies target specific antigens, offering precision in treating diseases such as cancer, autoimmune disorders, and infectious diseases. The market is driven by advancements in biotechnology, increasing prevalence of chronic diseases, and growing investment in personalized medicine, underscoring a trend towards more targeted and effective treatment modalities.

The Monoclonal Antibody Therapy Market is experiencing robust growth, fueled by advancements in biotechnology and increasing prevalence of chronic diseases. The oncology segment is the top-performing area, driven by the rising demand for targeted cancer treatments. Within this segment, the sub-segment focusing on checkpoint inhibitors is particularly noteworthy, offering significant therapeutic potential. The autoimmune disorders segment emerges as the second highest-performing area, with therapies targeting rheumatoid arthritis and multiple sclerosis showing strong promise. The infectious diseases segment is also gaining momentum, especially with monoclonal antibodies targeting viral infections such as COVID-19 and HIV. Innovations in bispecific antibodies are further propelling market growth, offering enhanced specificity and efficacy. The market is also witnessing a shift towards humanized and fully human monoclonal antibodies, reducing immunogenicity and improving patient outcomes. Ongoing research and development, coupled with strategic partnerships, are anticipated to drive future advancements and open new avenues for therapeutic interventions.

Monoclonal antibody therapy is gaining traction, with significant market share attributed to innovative pricing strategies and a surge in new product launches. This growth is fueled by advancements in biotechnology and a heightened focus on personalized medicine. Key players are enhancing their portfolios to cater to diverse therapeutic areas, driving competition and innovation. The pricing landscape remains dynamic, influenced by the need for cost-effective treatments and competitive pricing models. Competition in the monoclonal antibody therapy market is fierce, with major pharmaceutical companies vying for dominance. Regulatory influences, particularly in North America and Europe, shape market dynamics, ensuring safety and efficacy standards are met. Benchmarking against competitors reveals a trend toward strategic partnerships and mergers, enhancing market penetration. The regulatory environment continues to evolve, impacting market entry and expansion strategies. Companies are navigating these challenges by investing in research and development, seeking to capitalize on emerging opportunities in oncology and autoimmune diseases.

Geographical Overview:

The Monoclonal Antibody Therapy Market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains at the forefront, driven by advanced healthcare infrastructure and substantial investment in biopharmaceutical research. The region's strong focus on innovative therapies and a supportive regulatory environment further bolster its market position. Europe follows closely, with significant investments in biotechnology and a well-established healthcare system. The region's emphasis on personalized medicine and strong collaboration between academia and industry enhance its market potential. In Asia Pacific, rapid growth is fueled by increasing healthcare expenditure and rising prevalence of chronic diseases. Emerging economies like China and India are investing heavily in biopharmaceuticals, creating new growth pockets. Latin America and the Middle East & Africa are emerging markets with increasing potential. In Latin America, growing healthcare investments and improving access to advanced therapies are driving market expansion. Similarly, the Middle East & Africa are recognizing the importance of monoclonal antibody therapies in addressing unmet medical needs and fostering healthcare innovation.

The global monoclonal antibody therapy market is increasingly influenced by tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea, traditionally reliant on Western biopharmaceutical imports, are investing in domestic production capabilities to mitigate tariff impacts and ensure supply chain resilience. China is accelerating its innovation in biologics, spurred by geopolitical tensions and export restrictions, while Taiwan leverages its advanced manufacturing expertise to remain a pivotal player. Globally, the market is expanding, driven by rising demand for targeted therapies. By 2035, the market is expected to witness robust growth, contingent on geopolitical stability and diversified supply chains. Middle East conflicts, while indirectly affecting the market, could influence energy prices, thereby impacting production costs and logistics within the global supply chain.

Key Trends and Drivers:

The monoclonal antibody therapy market is experiencing robust growth, driven by advancements in biotechnology and rising prevalence of chronic diseases. A key trend is the increasing adoption of monoclonal antibodies in oncology, where they are used to target specific cancer cells, enhancing treatment efficacy. This precision medicine approach is gaining traction, leading to significant market expansion. Another trend is the development of biosimilars, which are more affordable alternatives to branded monoclonal antibodies. This is opening up new opportunities in emerging markets, where cost constraints have previously limited access to these therapies. Additionally, regulatory bodies are streamlining approval processes for biosimilars, further accelerating market growth. The market is also being driven by technological innovations in antibody engineering, enabling the creation of more potent and safer therapies. Moreover, partnerships between pharmaceutical companies and biotech firms are fostering research and development initiatives, leading to the introduction of novel monoclonal antibodies. These collaborations are crucial in addressing the unmet needs in various therapeutic areas, thus expanding the market landscape.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Functionality
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Deployment
• 2.9 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Murine
  • 4.1.2 Chimeric
  • 4.1.3 Humanized
  • 4.1.4 Human
  • 4.1.5 Bispecific
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Therapeutic Monoclonal Antibodies
  • 4.2.2 Diagnostic Monoclonal Antibodies
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Hybridoma Technology
  • 4.3.2 Recombinant DNA Technology
  • 4.3.3 Phage Display
  • 4.3.4 Transgenic Mice
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Cancer
  • 4.4.2 Autoimmune Diseases
  • 4.4.3 Infectious Diseases
  • 4.4.4 Cardiovascular Diseases
  • 4.4.5 Neurological Diseases
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Research Institutes
  • 4.5.3 Biopharmaceutical Companies
  • 4.5.4 Diagnostic Laboratories
• 4.6 Market Size & Forecast by Functionality (2020-2035)
  • 4.6.1 Neutralizing
  • 4.6.2 Cytotoxic
  • 4.6.3 Anti-inflammatory
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Upstream Processing
  • 4.7.2 Downstream Processing
• 4.8 Market Size & Forecast by Deployment (2020-2035)
  • 4.8.1 In-house
  • 4.8.2 Outsourced
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Preclinical
  • 4.9.2 Clinical
  • 4.9.3 Commercial

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Functionality
    • 5.2.1.7 Process
    • 5.2.1.8 Deployment
    • 5.2.1.9 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Functionality
    • 5.2.2.7 Process
    • 5.2.2.8 Deployment
    • 5.2.2.9 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Functionality
    • 5.2.3.7 Process
    • 5.2.3.8 Deployment
    • 5.2.3.9 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Functionality
    • 5.3.1.7 Process
    • 5.3.1.8 Deployment
    • 5.3.1.9 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Functionality
    • 5.3.2.7 Process
    • 5.3.2.8 Deployment
    • 5.3.2.9 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Functionality
    • 5.3.3.7 Process
    • 5.3.3.8 Deployment
    • 5.3.3.9 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Functionality
    • 5.4.1.7 Process
    • 5.4.1.8 Deployment
    • 5.4.1.9 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Functionality
    • 5.4.2.7 Process
    • 5.4.2.8 Deployment
    • 5.4.2.9 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Functionality
    • 5.4.3.7 Process
    • 5.4.3.8 Deployment
    • 5.4.3.9 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Functionality
    • 5.4.4.7 Process
    • 5.4.4.8 Deployment
    • 5.4.4.9 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Functionality
    • 5.4.5.7 Process
    • 5.4.5.8 Deployment
    • 5.4.5.9 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Functionality
    • 5.4.6.7 Process
    • 5.4.6.8 Deployment
    • 5.4.6.9 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Functionality
    • 5.4.7.7 Process
    • 5.4.7.8 Deployment
    • 5.4.7.9 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Functionality
    • 5.5.1.7 Process
    • 5.5.1.8 Deployment
    • 5.5.1.9 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Functionality
    • 5.5.2.7 Process
    • 5.5.2.8 Deployment
    • 5.5.2.9 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Functionality
    • 5.5.3.7 Process
    • 5.5.3.8 Deployment
    • 5.5.3.9 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Functionality
    • 5.5.4.7 Process
    • 5.5.4.8 Deployment
    • 5.5.4.9 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Functionality
    • 5.5.5.7 Process
    • 5.5.5.8 Deployment
    • 5.5.5.9 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Functionality
    • 5.5.6.7 Process
    • 5.5.6.8 Deployment
    • 5.5.6.9 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Functionality
    • 5.6.1.7 Process
    • 5.6.1.8 Deployment
    • 5.6.1.9 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Functionality
    • 5.6.2.7 Process
    • 5.6.2.8 Deployment
    • 5.6.2.9 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Functionality
    • 5.6.3.7 Process
    • 5.6.3.8 Deployment
    • 5.6.3.9 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Functionality
    • 5.6.4.7 Process
    • 5.6.4.8 Deployment
    • 5.6.4.9 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Functionality
    • 5.6.5.7 Process
    • 5.6.5.8 Deployment
    • 5.6.5.9 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Genmab
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Morpho Sys
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Macro Genics
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Immuno Gen
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Xencor
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Zymeworks
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Pieris Pharmaceuticals
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Ab Cellera Biologics
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Mab Vax Therapeutics
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Onco Immune
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Immunomedics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Alligator Bioscience
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Bio Invent International
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Crescendo Biologics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 F-star Therapeutics
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Adimab
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Harpoon Therapeutics
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 I- Mab Biopharma
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Cantargia
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us